Innovative Euro 250,000 Parenteral Nutrition Research Grant Awarded by Fresenius Kabi

Fresenius Kabi

2021/11/25 17:02

PR93196

 

BAD HOMBURG, Germany, Nov. 25, 2021 /PRNewswire=KYODO JBN/--

 

Fresenius Kabi was delighted to announce the winner of their innovative

JUMPstart education program and research grant on September 10, 2021. JUMPstart

is an initiative that aims to nurture research in the field of parenteral

nutrition through the mentoring, education and networking of clinicians and

researchers. The grant is awarded to help to advance novel, community-led

research in parenteral nutrition, to make a difference for critically ill

patients.

 

This year's winner is Professor Stefan Schaller M.D. of Charite –

Universitatsmedizin Berlin, Germany, for his proposal entitled "Improved muscle

metabolism by combination of muscle activation and protein substitution." This

cutting-edge study aims to explore the effect of protein substitution before

and after early, goal-directed mobilization in the acute phase of critical

illness. The announcement was made at the European Society for Clinical

Nutrition and Metabolism (ESPEN) Congress.

 

During the virtual awards ceremony, Professor Schaller said: "After working on

this research proposal for a long time, me and my research team are thrilled to

be able to now conduct the study, and I am very thankful to the generous grant

from Fresenius Kabi. I am very optimistic that this trial will have an impact

on nutrition therapy in critical care."

 

Professor Schaller took part in the program alongside 18 other participants

from around the world, including representation from Africa, Asia, Australia,

Europe, New Zealand, and North and South America. After four training sessions,

participants presented their research proposals to an independent international

scientific committee, which consisted of five field-leading experts: Professor

Mette Berger, Switzerland; Professor Olav Rooyackers, Sweden; Professor Tim

Friede, Germany; Professor Robert Martindale, USA; and Professor Ho-Seong Han,

South Korea. The committee was impressed by the high-quality level of all

proposals, and this made picking a winner extremely challenging.

 

Dr. Jos Simons, Executive Vice President at Fresenius Kabi, commented: "We are

absolutely delighted to be able to award this research grant to Professor

Schaller. Both the scientific committee and Fresenius Kabi were astounded by

his proposal and the positive impact it will have on clinical practice. We are

very excited for Professor Schaller to start this clinical study."

 

This is the second JUMPstart research grant worth Euro 250,000. The first

program of 19 participants completed in 2019, with the grant awarded to

dietician Lizl Veldsman, Tygerberg Academic Hospital in Cape Town, South

Africa.

 

With the JUMPstart education program and research grant, Fresenius Kabi

supports the next generation of clinical experts who will contribute to

advancement in nutrition therapy in critically ill patients.

 

Fresenius Kabi is a global healthcare company that specializes in lifesaving

medicines and technologies for infusion, transfusion and clinical nutrition.

The company's products and services are used to help care for critically and

chronically ill patients. Fresenius Kabi's product portfolio comprises a

comprehensive range of I.V. generic drugs, infusion therapies and clinical

nutrition products as well as the devices for administering these products. In

the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and

oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched.

Within transfusion medicine and cell therapies, Fresenius Kabi offers products

for collection of blood components and extracorporeal therapies.

 

With its corporate philosophy of "caring for life", the company is committed to

putting essential medicines and technologies in the hands of people who help

patients and finding the best answers to the challenges they face.

 

Fresenius Kabi employs around 40,500 people worldwide. In 2020, the company

reported sales of around Euro 7.0 billion. Fresenius Kabi AG is a wholly owned

subsidiary of the Fresenius SE & Co. KGaA healthcare group.

 

For more information, please visit www.fresenius-kabi.com

 

This release contains forward-looking statements that are subject to various

risks and uncertainties. Future results could differ materially from those

described in these forward-looking statements due to certain factors, e.g.

changes in business, economic and competitive conditions, regulatory reforms,

results of clinical trials, foreign exchange rate fluctuations, uncertainties

in litigation or investigative proceedings, and the availability of financing.

Fresenius Kabi does not undertake any responsibility to update the

forward-looking statements in this release.

 

Management Board: Michael Sen (Chairman), Marc Crouton, John Ducker, Dr. Oskar

Haszonits, Dr. Christian Hauer, Dr. Michael Schonhofen, Gerrit Steen

Chairman of the Supervisory Board: Stephan Sturm

Registered Office: Bad Homburg, Germany

Commercial Register: Amtsgericht Bad Homburg - HRB 11654

 

Contact: Emese Kamp

         PINK CARROTS Communications GmbH

         E-mail: emese.kamp@pinkcarrots.com  

         Phone: +49-69-4272614-141

 

Photo - https://mma.prnewswire.com/media/1693173/Fresenius_Kabi.jpg

Logo  - https://mma.prnewswire.com/media/1655430/Fresenius_Kabi_Logo.jpg

 

Source:  Fresenius Kabi

 

 

本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。

このプレスリリースには、報道機関向けの情報があります。

プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。

プレスリリース受信に関するご案内

SNSでも最新のプレスリリース情報をいち早く配信中